• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Journal of Clinical Microbiology >Molecular Characterization of Human Immunodeficiency Virus Type 1 (HIV-1) and HIV-2 in Yaoundé Cameroon: Evidence of Major Drug Resistance Mutations in Newly Diagnosed Patients Infected with Subtypes Other than Subtype B
【2h】

Molecular Characterization of Human Immunodeficiency Virus Type 1 (HIV-1) and HIV-2 in Yaoundé Cameroon: Evidence of Major Drug Resistance Mutations in Newly Diagnosed Patients Infected with Subtypes Other than Subtype B

机译：喀麦隆雅温得的人类免疫缺陷病毒1型（HIV-1）和HIV-2的分子特征：在新诊断的感染了B型以外的患者中主要耐药性突变的证据

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Prior to current studies on the emergence of drug resistance with the introduction of antiretroviral therapy (ART) in Cameroon, we performed genotypic analysis on samples from drug-naïve, human immunodeficiency virus (HIV)-infected individuals in this country. Of the 79 HIV type 1 (HIV-1) pol sequences analyzed from Cameroonian samples, 3 (3.8%) were identified as HIV-1 group O, 1 (1.2%) was identified as an HIV-2 intergroup B/A recombinant, and the remaining 75 (95.0%) were identified as HIV-1 group M. Group M isolates were further classified as subtypes A1 (n = 4), D (n = 4), F2 (n = 6), G (n = 12), H (n = 2), and K (n = 1) and as circulating recombinant forms CRF02_AG (n = 41), CRF11_cpx (n = 1), and CRF13_cpx (n = 2). Two pol sequences were identified as unique recombinant forms of CRF02_AG/F2 (n = 2). M46L (n = 2), a major resistance mutation associated with resistance to protease inhibitors, was observed in 2/75 (2.6%) group M samples. Single mutations associated with resistance to nucleoside reverse transcriptase inhibitors (T215Y/F [n = 3]) and nonnucleoside reverse transcriptase inhibitors (V108I [n = 1], L100I [n = 1], and Y181C [n = 2]) were observed in 7 of 75 (9.3%) group M samples. None of the patients had any history of ART exposure. Population surveillance of transmitted HIV drug resistance is required and should be included to aid in the development of appropriate guidelines.
机译：在喀麦隆采用抗逆转录病毒疗法（ART）进行耐药性出现的最新研究之前，我们对来自该国未受过人类免疫缺陷病毒（HIV）感染的个体的样本进行了基因型分析。从喀麦隆样本中分析的79个HIV 1型（HIV-1）pol序列中，有3个（3.8％）被鉴定为HIV-1组O，1个（1.2％）被鉴定为HIV-2组间B / A重组，其余75个（95.0％）被鉴定为HIV-1组M。M组分离株进一步分为亚型A1（n = 4），D（n = 4），F2（n = 6），G（n = 12），H（n = 2）和K（n = 1）以及循环重组形式CRF02_AG（n = 41），CRF11_cpx（n = 1）和CRF13_cpx（n = 2）。两个pol序列被确定为CRF02_AG / F2的独特重组形式（n = 2）。在2/75（2.6％）M组样品中观察到与蛋白酶抑制剂耐药相关的主要耐药突变M46L（n = 2）。与核苷逆转录酶抑制剂（T215Y / F [n = 3]）和非核苷逆转录酶抑制剂（V108I [n = 1]，L100I [n = 1]和Y181C [ n = 2]），在75个（9.3％）M组样本中有7个被观察到。没有患者有ART暴露史。需要对传播的艾滋病毒耐药性进行人群监测，并应纳入监测以帮助制定适当的指南。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号